PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.64%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
13.14%
Gross profit growth similar to CVE's 13.59%. Walter Schloss would assume both firms track common industry trends.
-2020.00%
Negative EBIT growth while CVE is at 273.70%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-4550.00%
Negative operating income growth while CVE is at 52.68%. Joel Greenblatt would press for urgent turnaround measures.
-165.00%
Negative net income growth while CVE stands at 488.36%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-165.22%
Negative EPS growth while CVE is at 562.91%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-177.27%
Negative diluted EPS growth while CVE is at 568.56%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.59%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
0.04%
Slight or no buyback while CVE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
1.61%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
-14.41%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-45.30%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
10.77%
10Y revenue/share CAGR under 50% of CVE's 91.41%. Michael Burry would suspect a lasting competitive disadvantage.
-10.27%
Negative 5Y CAGR while CVE stands at 138.72%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
19.45%
Positive 3Y CAGR while CVE is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
5.42%
10Y OCF/share CAGR under 50% of CVE's 103.93%. Michael Burry would worry about a persistent underperformance in cash creation.
53.88%
Below 50% of CVE's 609.81%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
25.98%
3Y OCF/share CAGR above 1.5x CVE's 8.20%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
94.58%
Net income/share CAGR at 50-75% of CVE's 154.84%. Martin Whitman might question if the firm’s product or cost base lags behind.
-137.68%
Negative 5Y net income/share CAGR while CVE is 132.25%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
34.78%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-38.35%
Negative equity/share CAGR over 10 years while CVE stands at 15.08%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1.32%
Negative 5Y equity/share growth while CVE is at 14.26%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
112.72%
3Y equity/share CAGR above 1.5x CVE's 37.03%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
19.47%
10Y dividend/share CAGR above 1.5x CVE's 2.91%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
224.25%
5Y dividend/share CAGR 1.25-1.5x CVE's 191.80%. Bruce Berkowitz verifies that high dividend hikes remain sustainable, not a sign of over-distribution.
48.27%
Below 50% of CVE's 379.49%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
12.58%
AR growth well above CVE's 13.58%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
1.87%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-0.86%
We have a declining book value while CVE shows 1.18%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.39%
Debt growth far above CVE's 1.30%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.19%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.